Sandoz To Acquire Retinal Disease Biosimilar For $170M
By Najiyya Budaly · January 22, 2024, 6:09 PM GMT
Sandoz Group AG said on Monday that it will buy a therapy for retinal diseases from U.S. biopharmaceutical company Coherus BioSciences Inc. for $170 million in cash, as the Swiss-German generic drugs...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login